Adding
UPTRAVI® (selexipag)

 
PAH keeps progressing
Keep exploring ways to help delay it.
Learn more about UPTRAVI®
What is UPTRAVI®?
UPTRAVI® is a prescription medicine used to treat pulmonary arterial hypertension (PAH, WHO Group 1), which is high blood pressure in the arteries of your lungs.1
UPTRAVI® can help delay (slow down) the progression of your disease and lower your risk of being hospitalized for PAH.1
It is not known if UPTRAVI® is safe and effective in children.1
Watch this video
to learn more
There are steps you can take that may delay PAH progression and it starts with talking to your doctor.
IN A CLINICAL TRIAL
UPTRAVI® reduced the risk of PAH disease progression* by 40%.1
27% of patients treated with UPTRAVI® experienced a PAH disease progression event vs 41.6% of patients not taking UPTRAVI®.1
UPTRAVI® reduced the risk of PAH-related hospitalizations. This benefit was demonstrated in a clinical trial comparing patients taking UPTRAVI® to those not taking UPTRAVI®. Patients took UPTRAVI® for an average of 1.4 years.1
In this same clinical trial, patients taking UPTRAVI® walked an average of 12 meters (about 39 feet) farther than patients not taking UPTRAVI®, as measured by the 6-minute walk distance (6MWD).1
*In a clinical trial of UPTRAVI®, PAH disease progression was defined as a serious event, such as hospitalization for PAH; the need to start injectable PAH medications or chronic oxygen therapy; lung transplantation; a decline in 6-minute walk distance (6MWD) combined with worsening of functional class (FC) or need for additional PAH therapy; or death.
How the study was conducted:
UPTRAVI® was studied in the largest trial of any FDA-approved PAH treatment1
  • The trial included 1156 total PAH patients.
    • Compared 574 patients taking UPTRAVI® with 582 patients taking placebo (a sugar pill)
  • 80% of enrolled patients were treated with an endothelin receptor antagonist (ERA), phosphodiesterase type-5 inhibitor (PDE-5 inhibitor), or both for PAH
  • 20% of enrolled patients were not on any PAH treatment
  • Nearly all patients were FC II or FC III (PAH patients range from FC I to FC IV)
  • Patients taking UPTRAVI® were treated for an average of 1.4 years during this study
  • The trial included the most scleroderma-related PAH patients of any PAH trial (170 out of 1156)3,4
Play a role in the conversation. Ask your doctor ABOUT UPTRAVI®.
Even on a good day, your PAH could be progressing.5
UPTRAVI® can help delay disease progression when used alone or in combination with other PAH medications (an ERA, a PDE-5i or both).1
Learn how to discuss UPTRAVI® with your doctor and start exploring an additional angle to help delay disease progression by downloading this doctor discussion guide.
DOWNLOAD DOCTOR DISCUSSION GUIDE
IMPORTANT SAFETY INFORMATION
EXPAND +
+
IMPORTANT SAFETY INFORMATION
+
What is UPTRAVI®?
IMPORTANT SAFETY INFORMATION
References: 1. UPTRAVI® (selexipag) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250-2294. 3. Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50(2). 4. Aithala R, Alex A, Debashish D. Pulmonary hypertension in connective tissue diseases: an update. Int J Rheum Dis. 2017;20:5-24. 5. Lau EM, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12(3):143-155.
×